Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard B Warren

Showing results (181-190 of 257) with videos related to

Pageof 26
Sort By:
Lancet (London, England)|July 21, 2024
Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trialsRobert Bissonnette, Richard B Warren, Andreas Pinter, et al.
The British Journal of Dermatology|January 25, 2023
The effect of immunomodulators on seroconversion after BNT162b2 and AZD1222 vaccines in patients with immune-mediated inflammatory diseases: a prospective cohort studyAli Al-Janabi, Amelle Ra, Zoe Littlewood, et al.
The British Journal of Dermatology|July 17, 2025
Mendelian randomization identifies OX40 as a potential mediator of the effects of cigarette smoking in palmoplantar pustulosisAlice Smail, Nick Dand, Xinyue Liu, et al.
The British Journal of Dermatology|February 10, 2023
Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for patients with moderate-to-severe psoriasis: a cohort study from BADBIROras A Alabas, Kayleigh J Mason, Zenas Z N Yiu, et al.
The Journal of Dermatological Treatment|June 30, 2024
Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trialsNeil J Korman, Richard B Warren, Jerry Bagel, et al.
The Journal of Investigative Dermatology|August 22, 2018
Defining the Therapeutic Range for Adalimumab and Predicting Response in Psoriasis: A Multicenter Prospective Observational Cohort StudyNina Wilkinson, Teresa Tsakok, Nick Dand, et al.
American Journal of Clinical Dermatology|June 23, 2019
Feasibility and Utility of the Psoriasis Symptom Inventory (PSI) in Clinical Care Settings: A Study from the International Psoriasis CouncilBruce Strober, Peter C M van de Kerkhof, Kristina Callis Duffin, et al.
Immunotherapy|May 8, 2023
Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-1 study): a plain language summaryApril W Armstrong, Melinda Gooderham, Richard B Warren, et al.
Lancet (London, England)|April 12, 2025
Reflections on chronic hand eczema - Authors' replyRobert Bissonnette, Richard B Warren, Andreas Pinter, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 7, 2024
Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2)Bruce Strober, Andrew Blauvelt, Richard B Warren, et al.
Pageof 26

Showing results (181-190 of 257) with videos related to

Sort By:
Pageof 26
Lancet (London, England)|July 21, 2024
Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trialsRobert Bissonnette, Richard B Warren, Andreas Pinter, et al.
The British Journal of Dermatology|January 25, 2023
The effect of immunomodulators on seroconversion after BNT162b2 and AZD1222 vaccines in patients with immune-mediated inflammatory diseases: a prospective cohort studyAli Al-Janabi, Amelle Ra, Zoe Littlewood, et al.
The British Journal of Dermatology|July 17, 2025
Mendelian randomization identifies OX40 as a potential mediator of the effects of cigarette smoking in palmoplantar pustulosisAlice Smail, Nick Dand, Xinyue Liu, et al.
The British Journal of Dermatology|February 10, 2023
Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for patients with moderate-to-severe psoriasis: a cohort study from BADBIROras A Alabas, Kayleigh J Mason, Zenas Z N Yiu, et al.
The Journal of Dermatological Treatment|June 30, 2024
Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trialsNeil J Korman, Richard B Warren, Jerry Bagel, et al.
The Journal of Investigative Dermatology|August 22, 2018
Defining the Therapeutic Range for Adalimumab and Predicting Response in Psoriasis: A Multicenter Prospective Observational Cohort StudyNina Wilkinson, Teresa Tsakok, Nick Dand, et al.
American Journal of Clinical Dermatology|June 23, 2019
Feasibility and Utility of the Psoriasis Symptom Inventory (PSI) in Clinical Care Settings: A Study from the International Psoriasis CouncilBruce Strober, Peter C M van de Kerkhof, Kristina Callis Duffin, et al.
Immunotherapy|May 8, 2023
Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-1 study): a plain language summaryApril W Armstrong, Melinda Gooderham, Richard B Warren, et al.
Lancet (London, England)|April 12, 2025
Reflections on chronic hand eczema - Authors' replyRobert Bissonnette, Richard B Warren, Andreas Pinter, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 7, 2024
Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2)Bruce Strober, Andrew Blauvelt, Richard B Warren, et al.
Pageof 26